Skip to main content
SpringerLink
Log in

Isolated Hepatic Perfusion: Treating Unresectable Liver Metastases

  • Conference paper
Liver and Pancreatic Diseases Management

Part of the book series: Advances in Experimental Medicine and Biology ((volume 574))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.

    Article  PubMed  Google Scholar 

  2. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230:309–321.

    Article  PubMed  CAS  Google Scholar 

  3. Rothenberg MC, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluourouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059–2069.

    Article  PubMed  CAS  Google Scholar 

  4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  6. Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969;23:198–202.

    Article  PubMed  CAS  Google Scholar 

  7. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239–251.

    Article  PubMed  CAS  Google Scholar 

  8. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–390.

    PubMed  CAS  Google Scholar 

  9. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Höffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–2223.

    Article  PubMed  CAS  Google Scholar 

  10. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. Acta Opthalmol Scand. 1995;73:340–344.

    Article  CAS  Google Scholar 

  11. Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399–3408.

    PubMed  Google Scholar 

  12. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc. 2000;98:471–492.

    PubMed  CAS  Google Scholar 

  13. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–336.

    Article  PubMed  CAS  Google Scholar 

  14. Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transplant Surg. 1999;5:65–80.

    Article  CAS  Google Scholar 

  15. Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol. 1954;30:969–985.

    PubMed  CAS  Google Scholar 

  16. Lin G, Lunderquist A, Hägerstrand I, Boijsen E. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery. 1984;96:517–526.

    PubMed  CAS  Google Scholar 

  17. Ausman RK. Development of a technic for isolated perfusion of the liver. NYState J Med. 1961;61:3393–3397.

    Google Scholar 

  18. Lienard D, Ewalenko P, Delmotti JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60.

    PubMed  CAS  Google Scholar 

  19. Eggermont AMM, Koops HS, Klausner JM, Kroon BBR, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector J-C, Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg. 1996;224:756–765.

    Article  PubMed  CAS  Google Scholar 

  20. Lienard D, Eggermont AM, Schraffordt-Koops H, Kroon BB, Roisenkaimer F, Autier P, Lejeune FJ. Isolated perfusion of the limb with high-dose tumor necrosis factor, interferon gamma and melphalan for melanoma stage III. Results of a multicentre pilot study. Melanoma Res. 1994;4:21–26.

    PubMed  Google Scholar 

  21. di Filippo F, Anza M, Rossi CR, Cavaliere F, Botti C, Lise M, Garinei R, Giannarelli D, Vasselli S, Zupi G, Cavaliere R. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol. 1998;14:215–223.

    Article  PubMed  Google Scholar 

  22. Libutti SK, Bartlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000;191:519–530.

    Article  PubMed  CAS  Google Scholar 

  23. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176–187.

    Article  PubMed  CAS  Google Scholar 

  24. Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416–424.

    Article  PubMed  CAS  Google Scholar 

  25. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am. 1998;4:2–11.

    PubMed  Google Scholar 

  26. Lans TE, Bartlett DL, Libutti SK, Gnant MFX, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR Jr. Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001;7:784–790.

    PubMed  CAS  Google Scholar 

  27. Rothbarth J, Pijl ME, Vahrmeijer AL, Hartgrink HH, Tijl FG, Kuppen PJ, Tollenaar RA, van de Velde CJ. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003;90:1391–1397.

    Article  PubMed  CAS  Google Scholar 

  28. Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresnev T. Isolated hepatic prefusion for the treatment of patients with colorectal cancer (CRC) liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005 Feb;12(2):138–144.

    Article  PubMed  Google Scholar 

  29. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, Tarkkanen A, Kivela T. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366–2372.

    Article  PubMed  CAS  Google Scholar 

  30. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–3070.

    PubMed  CAS  Google Scholar 

  31. Alexander HR, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresnev T. Hyperthermic isolated hepatic perfusion (IHP) using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343–6349.

    PubMed  CAS  Google Scholar 

  32. Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67–72.

    Article  PubMed  CAS  Google Scholar 

  33. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–976.

    Article  PubMed  CAS  Google Scholar 

  34. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589–2595.

    PubMed  CAS  Google Scholar 

  35. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.

    Article  PubMed  CAS  Google Scholar 

  36. Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg. 1982;6:66–75.

    Article  PubMed  CAS  Google Scholar 

  37. Feldman ED, Wu PC, Gnant MXF, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR Jr. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J GI Surg. 2004;8:200–207.

    Article  Google Scholar 

  38. Hafström LR, Holmberg SB, Naredi PLJ, Lindnér PG, Bengtsson A, Tidebrant G, Scherstén TSO. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994;3:103–108.

    Article  PubMed  Google Scholar 

  39. Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery. 2004;136:1176–1182.

    Article  PubMed  Google Scholar 

  40. Hafström L, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNFα and melphalan: Swedish experience. Recent Results Cancer Res. 1998;147:120–126.

    PubMed  Google Scholar 

  41. Lindner P, Fjalling M, Hafström L, Nielsen H, Mattson H. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia tumour necrosis factor alpha and melphalan. Eur J Surg Oncol. 1999;25:179–185.

    Article  PubMed  CAS  Google Scholar 

  42. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Seidel G, Alexander HR. A phase I feasibility study of hepatic arterial melphalan infusion with hepatic arterial melphalan infusion with hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. Am Soc Clin Oncol Proc. 2003;22:282 (Abstract)

    Google Scholar 

  43. Marinelli A, Vahrmeijer AL, van de Velde CJ. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res. 1998;147:83–94.

    PubMed  CAS  Google Scholar 

  44. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–1489.

    PubMed  CAS  Google Scholar 

  45. Vahrmeijer AL, Van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 2000;82:1539–1546.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Metabolism Section, Surgery Branch, National Cancer Institute, CRC, Rm. 4W-5952, 10 Center Drive, MSC 1201, Bethesda, MD, 20892-1201, USA

    Jeffrey M. Farma, James F. Pingpank & H. Richard Alexander

Authors
  1. Jeffrey M. Farma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James F. Pingpank
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Richard Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Imperial College School of Medicine, Hammersmith Hospital, London, UK

    Nagy A. Habib  & Ruben Canelo  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer

About this paper

Cite this paper

Farma, J.M., Pingpank, J.F., Alexander, H.R. (2006). Isolated Hepatic Perfusion: Treating Unresectable Liver Metastases. In: Habib, N.A., Canelo, R. (eds) Liver and Pancreatic Diseases Management. Advances in Experimental Medicine and Biology, vol 574. Springer, Boston, MA . https://doi.org/10.1007/0-387-29512-7_1

Download citation

Publish with us

Policies and ethics

Search

Navigation